In this Breastcancer.org podcast, Brian Wojciechowski, M.D., Breastcancer.org’s medical adviser, talks about four studies that were presented at the 2015 San Antonio Breast Cancer Symposium, December 8-12, including studies that offer encouraging news about treatment for women diagnosed with triple-negative disease and metastatic, HER2-positive breast cancer. Listen to the podcast to hear Dr. Wojciechowski explain: what luminal A breast cancer is and why women diagnosed with this subtype didn’t seem to benefit from chemotherapy after surgery why adding carboplatin to a standard chemotherapy before surgery for triple-negative breast cancer improved pathologic complete response rates and what this means for women with triple-negative disease why postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer who are taking an aromatase inhibitor and have experienced bone loss might want to consider taking the targeted therapy denosumab results showing that Kadcyla improves overall survival in women diagnosed with metastatic, HER2-positive breast cancer that has stopped responding to Herceptin and Tykerb

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related